Eye imaging detects Parkinson changes
- Trial ID
- NCT03233646
- Official Title
- Evaluating the Retinal and Choroidal Microvasculature and Structure Using Multimodal Retinal and Choroidal Imaging in Neurodegenerative Disease: iMIND Research Study
- Goal
- Eye imaging detects Parkinson changes
- Status
- RECRUITING
- Sponsor
- Duke University
- Study Type
- OBSERVATIONAL
- Enrollment
- 2000 participants
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, Multiple Sclerosis, Huntington Disease, Lewy Body Dementia, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis (ALS), APOE-4 Positive, Traumatic Brain Injury, Concussion, Post-Traumatic Stress Disorder, Down Syndrome, Neuro-Degenerative Disease, Normal Cognition
- Interventions
- Retinal and Choroidal Imaging
Plain-Language Summary
The team is looking for signs in the retina and choroid that mirror Parkinson's-related brain changes, with the hope that simple eye scans could serve as an easy biomarker for neurodegeneration. They use noninvasive multimodal imaging to map tiny blood vessels and tissue layers in the back of the eye, and these scans do not involve any drugs or changes to Parkinson's medications. Adults 18 and older with Parkinson's can join, as can people with other neurodegenerative conditions and people without cognitive disease, as long as they can complete the eye tests. People with eye problems that would affect imaging or who had intraocular surgery other than cataract removal are not eligible.
Locations
- Duke University Medical Center, Durham, North Carolina, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Retinal and Choroidal Imaging. The team is looking for signs in the retina and choroid that mirror Parkinson's-related brain changes, with the hope that simple eye scans could serve as an easy biomarker for neurodegeneration. They use noninvasive multimodal imaging to map tiny blood vessels and tissue layers in the back of the eye, and these scans do not involve any drugs or changes to Parkinson's medications. Adults 18 and older with Parkinson's can join, as can people with other neurodegenerative conditions and people without cognitive disease, as long as they can complete the eye tests. People with eye problems that would affect imaging or who had intraocular surgery other than cataract removal are not eligible.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 9 years and 5 months.